

## Fractionated radiotherapy for spinal tumors: A literature review regarding spinal glioma, ependymoma, and meningioma

Raphael Bodensohn<sup>o</sup>, Erik Haehl<sup>o</sup>, Claus Belka<sup>o</sup> and Maximilian Niyazi

*Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany (R.B., M.N.); Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Tübingen, Germany (R.B., M.N.); Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany (R.B., E.H., C.B., M.N.); Bavarian Cancer Research Center (BZKF), Munich, Germany (C.B.); German Cancer Consortium (DKTK), partner site Tübingen, a partnership between DKFZ and University Hospital Tübingen, Tübingen, Germany (M.N.)*

**Corresponding Author:** Maximilian Niyazi, MD, MSc, Department for Radiation Oncology, University Hospital Tübingen, Hoppe-Seyler-Straße 3, 72076 Tübingen, Germany ([Maximilian.Niyazi@med.uni-tuebingen.de](mailto:Maximilian.Niyazi@med.uni-tuebingen.de))

### Abstract

Radiation therapy plays a vital role in the management of primary spinal tumors in adults. However, due to the rarity of these tumor types, the literature on optimal treatment indications and radiation doses is limited. Many treatment recommendations are extrapolated from their cranial counterparts, where more data are available. Despite the absence of prospective data, numerous retrospective studies have provided valuable insights to guide treatment decisions until more comprehensive data become available. This review provides an overview of the most relevant literature, with a specific focus on spinal gliomas, ependymomas, and meningiomas, in the context of the role of radiation therapy.

### Keywords

astrocytoma | ependymoma | glioma | meningioma | myxopapillary

Spinal tumors are a notably rare disease in adults, with an estimated frequency of only around 1 case per 1 000 000 persons per year.<sup>1</sup> In addition to surgical intervention, radiotherapy (RT) plays a significant role in managing these tumors. Nevertheless, it is of utmost importance to recognize that the spinal cord is exceptionally sensitive to radiation exposure, which poses a substantial risk of causing myelopathy. Such complications can significantly diminish a patient's quality of life and even prove to be life threatening.<sup>2</sup> This inherent sensitivity must be carefully taken into consideration when prescribing treatment doses for spinal tumor therapy. According to the QUANTEC (Quantitative Analysis of Normal Tissue Effects in the Clinic) estimations, the likelihood of myelopathy is projected at 0.2%, 6%, and 50% for dose levels of 50Gy, 60Gy, and 69Gy, respectively, when considering equivalent doses of 2Gy.<sup>3</sup> For diseases located outside the spine, a common conventional dose constraint for the spinal cord is often established at 45Gy. The aim is to minimize the potential

risk for myelopathy, particularly as the spinal cord serves as an organ at risk. In the context of spinal RT, higher doses are necessary to achieve an effective local control. As a result, doses of up to 54Gy are commonly used, even though they harbor a risk of approximately 1%–2% for myelopathy.<sup>4</sup> To justify this risk, a certain level of treatment success must be attainable.

There are mainly 2 types of radiation-induced myelopathy: early and late myelopathy. Early myelopathy appears typically 2–4 months after radiotherapy, and is associated with large volumes of irradiated spine than higher doses.<sup>5</sup> It typically shows electrifying pain, the L'hermitte syndrome, and is mostly self-limiting after a few months. Late myelopathy is associated with higher irradiation doses, often leads to serious neurological deficits, and can be permanent.<sup>5</sup> Treatment usually consists of corticosteroids. Similar to radionecrosis after cranial radiotherapy,<sup>6,7</sup> bevacizumab is a potential treatment option for radiation myelopathy and has shown promising results in some case reports.<sup>8–11</sup> Another recent case report

suggests intravenous immune globulin as a treatment for delayed radiation myelopathy.<sup>12</sup> To conclude, there are several treatment approaches to this serious adverse effect, but none of them is reliable and mostly only alleviates the symptoms. Avoiding this radiation-induced toxicity should, therefore, be of high priority while treating tumors of the spinal cord.

The following review article provides an overview of the existing literature pertaining to radiation schemes and techniques utilized in the management of some of the most prevalent primary spinal tumors, namely spinal glioma, spinal ependymoma, and spinal meningioma.


## Methods

The literature research was conducted using the PubMed database. The following search terms were entered as primary search: “((spinal[title] OR spine[title])) AND ((radiation[Title/Abstract] OR (irradiation[Title/Abstract] OR (radiotherapy[Title/Abstract] OR (proton[Title/Abstract] OR (radiosurgery[title/abstract])) AND ((glioma[title] OR (gliomas[title] OR (Astrocytoma[title] OR (astrocytomas[title] OR (glioblastoma[title] OR (glioblastomas[title]))” for spinal glioma, “((spinal[title] OR spine[title])) AND ((radiotherapy[title/abstract] OR (radiation[title/abstract] OR (proton[Title/Abstract] OR (radiosurgery[title])) AND ((ependymoma[title] OR (ependymomas[title]))” for spinal ependymoma, and “((spinal[title] OR spine[title])) AND ((radiotherapy[title/abstract] OR (radiation[title/abstract] OR (proton[Title/Abstract] OR (radiosurgery[title/abstract])) AND ((meningioma[Title] OR (meningiomas[title]))” for spinal meningiomas. The abstracts of the resulting articles were screened for suitable articles. The results of the PubMed search are shown in [Figure 1](#). Additionally, the references of the retrieved articles were used to identify additional articles. [Table 1](#) gives an overview of selected studies from the literature.

## Spinal Glioma

Spinal gliomas or astrocytomas are not categorized as a distinct entity by the 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors.<sup>32</sup> Instead, they are considered a subset of the more commonly recognized cerebral gliomas, encompassing grades 1–4.<sup>32</sup> Due to their rare occurrence compared to cranial gliomas, treatment approaches are often copied from strategies applied to their cranial counterparts, such as gross total resection (GTR), RT, or the use of temozolomide.<sup>13,33–35</sup> Nevertheless, in contrast to cranial gliomas, the available literature lacks clear and well-defined treatment recommendations. The National Comprehensive Cancer Network (NCCN) guideline (Version 1.2023) does not give any specific treatment recommendations and refers to the treatment of spinal glioma directly to their cranial counterparts. Basically, resection should be considered as a primary treatment for spinal, for local control, and preserving of neurological functions.<sup>34</sup> The combination of surgery and radiotherapy provided significantly better results than RT alone (mean overall survival [OS] 63.0 months vs. 2.7 months,  $P = .001$ ).<sup>13</sup> Also, patients receiving RT additively to resection seem to benefit, compared to resection alone ( $P = .001$  for 36 non-pilocytic,  $P = .14$  for 43 pilocytic).<sup>21</sup> A meta-analysis by Hamilton et al. was only partly able to reproduce these results, with RT decreasing mortality in high-grade spinal glioma (HGSG) and increasing mortality for low-grade spinal glioma (LGSG): for RT versus no RT, the 5-year OS rate was 30.3% versus 22.2% in HGSG and 51.5% versus 79.5% in LGSG, the 10-year OS rate was 21.3% versus 14.2% for HGSG and 42.3% versus 74.3% versus for LGSG, respectively.<sup>36</sup> However, it is important to acknowledge the potential bias in these results, as the cohorts receiving RT and those without might exhibit differences that could impact the outcomes.

Due to the risk of myelopathy, the dose applied to spinal gliomas needs to be lower than in cranial gliomas. However, the dose still has to be sufficient for tumor



**Figure 1.** Flowchart showing the PubMed literature search with the entered terms described in the Methods section.

**Table 1.** Overview of the Literature on Spinal Glioma and Ependymoma Including the Oxford Level of Evidence Estimated by the authors

Article	Patients	Treatment	Irradiation dose	Survival
Corradini et al. <sup>13</sup>	n = 16 7 primary glioma 9 secondary glioma 10 WHO IV 4 WHO III 2 WHO II	RT 16 (10 RT + TMZ) GTR 1 STR 9 PE 7	Median dose 45Gy (range 30–54Gy) median dose per fraction 1.8Gy (range 1.8–3.0Gy)	Median OS 6 months Mean OS $\geq$ 45Gy 64.0 months vs. mean OS < 45Gy, 2.5 months ( $P < .001$ ) Mean OS Surgery + RT 63.9 months vs. mean RT 2.7 months ( $P < .001$ )
Rodrigues et al. <sup>14</sup>	n = 52 48 astrocytoma 2 oligodendroglioma 2 mixed glioma	RT 52 GTR 5 STR 20 PE 27	median dose 50Gy in 25fx (20Gy in 10fx to 60Gy in 30fx)	5-y OS 54% 5-y PFS 58% 10-y OS 45% 10-y PFS 43%
Zorlu et al. <sup>15</sup>	n = 26 20 grades I–II 4 grade III	RT 26 GTR 2 STR 10 PE 14	median dose 49.5Gy (range 35–60Gy) median fraction dose 1.5Gy (range 1–2Gy)	5-y OS 45% 5-y PFS 40% 5-y OS > 45Gy 48% vs. 5-y OS $\leq$ 45Gy 29% $P = .2$
Shirato et al. <sup>16</sup>	n = 36 7 astrocytoma 4 anaplastic astrocytoma 2 glioblastoma 18 ependymoma 4 myxopapillary ependymoma	RT 21 GTR 14 (1 Astrocytoma, 13 Ependymoma) STR 8 PE 14	Astrocytoma median dose 45Gy (35–50Gy) High-grade astrocytic tumors 50Gy (40–65Gy) Ependymal tumors 40Gy (30–50Gy)	5-y OS 96% (ependymoma) 5-y OS 50% (astrocytoma)
Kahn et al. <sup>17</sup>	n = 32 15 ependymoma 17 astrocytoma 1 oligodendroglioma	RT 32 (10 proton) STR 19 (8 astrocytoma, 11 ependymoma) PE 11 (8 astrocytoma, 3 ependymoma)	mean 51Gy (n = 22) (range 45–54.45Gy)	5-y OS 65% 5-y PFS 61% 5-y OS (ependymoma) 86% 5-y OS (astrocytoma) 52%
Garcia et al. <sup>18</sup>	n = 37 (14 children) 26 intramedullary (14 Astrocytoma, 8 ependymoma, 3 unknown, 1 diffuse histiocytic lymphoma) 11 conus/cauda (1 astrocytoma, 10 ependymoma)	RT 37 GTR 1 STR 8 PE 14	Range 30–50Gy Range fraction dose 1.7–2.0Gy	5-y OS 70% 10-y OS 58% <40Gy 90% died of recurrence $\geq$ 40Gy 75% control of tumor
LinStadt et al. <sup>19</sup>	n = 42 21 ependymoma 12 low-grade astrocytoma 3 high-grade glioma 39 local RT 3 craniospinal RT	RT 42 (39 local, 3 craniospinal) GTR 15 (15 ependymoma) STR 19 (14 ependymoma, 5 astrocytoma) PE (5 ependymoma, 10 astrocytoma)	Mean 50Gy (range 45.0–54.7Gy) (n = 39) 3 received craniospinal RT	10-y OS 91% (low-grade astrocytoma) 10-y OS 93% (ependymoma) High-grade astrocytoma lived not longer than 8 months
Sandler et al. <sup>20</sup>	n = 21 18 LGSG 2 HGSG 15 RT 3 GTR, STR 7, PE 11	RT 15 GTR 3 STR 7 PE 11	Range 35.25–60.00 Gy	5-y OS 57% 5-y PFS 44% 10-y OS 57% 10-y PFS 30%
Minehan et al. <sup>21</sup>	n = 136 69 pilocytic astrocytoma 40 astrocytoma 19 anaplastic astrocytoma 8 glioblastoma	RT 102 GTR 22 STR 34 PE 80	Median 48.95Gy $\pm$ 8.04Gy	Median OS (pilocytic) 39.9 years Median OS (astrocytic) 1.85 years Median OS (astrocytic) > 35Gy 26 months vs. median OS (astrocytic) $\leq$ 35Gy: 9 months ( $P = .04$ )
Nunna et al. <sup>22</sup>	n = 396 (grade III and IV)	RT 277 (78 IMRT, 5 proton) GTR 23 STR 198 Extent unknown 105	30.9Gy $\pm$ 22.9Gy fraction dose of 1.9Gy $\pm$ 6.1Gy	Mean OS 24.5 months
Shaw et al. <sup>23</sup>	n = 22 12 ependymoma 10 myxopapillary ependymoma	RT 8 GTR 8 STR 11 PE 3	Median 50Gy Range 36–57Gy	5-y and 10-y OS 95% 5-y PFS 81% 10-PFS 71% $\leq$ 50Gy 35% failure >50Gy 20% failure

Table 1. Continued

Article	Patients	Treatment	Irradiation dose	Survival
Choi et al. <sup>24</sup>	n = 45 (all astrocytoma) WHO I 6 WHO II 14 WHO III 12 WHO IV 13	RT 45 (37 postOp, 6 definitiv, 6 salvage, 4 craniospinal) GTR 6 STR 18 PTR 6 PE 3	Median 50.4Gy (range 42.5–54.0Gy) Median fraction 1.8Gy (range 1.5–2.5Gy)	Median OS 52 months Median PFS 24 months
Byun et al. <sup>25</sup>	n = 25 Grade 1 12 Grade 2 12 Grade 3 1 6 myxopapillary	RT 25 (21 local, 4 craniospinal)	Range 44.0–59, 4Gy Range lumbosacral 57–59, 4Gy Range cervicothoracic 45–50.4Gy	5-y OS 83.7% 5-y PFS 70.8%
Tsai et al. <sup>26</sup>	n = 51 All myxopapillary	RT 31 GTR 28 STR 22 PE 1	Median 50.4Gy (range 44.2–60Gy) Median fraction 1.8Gy (range 1.5–2Gy)	median OS 11 y 10-y OS 93% 10-y PFS 63%
Lee SH et al. <sup>27</sup>	n = 88 24 myxopapillary 61 ependymoma 3 anaplastic	RT 20 GTR 72 STR 15 PTR 1	Range 45–50Gy Range fraction 1.5–2Gy	5-y PFS 87% 10-y PFS 89%
Pica et al. <sup>28</sup>	n = 85 All myxopapillary	RT 47 GTR 40 STR 43 PE 2	Median 50.4Gy (range 22.2–59.4Gy) Fraction 1.8 (range 1.5–2.0Gy)	5-y PFS 67.5% 5-y PFS OP 50.4% 5-y PFS OP + RT 74, 8%
Wahab et al. <sup>29</sup>	n = 22 Grade 2 13 grade 1 9 (myxopapillary)	RT 22 (20 postOp, 2 salvage) GTR 2 STR 20	Median 45.0Gy (range 30.0–54.0Gy) Median fraction 1.8Gy (range 1.5– 2.5Gy)	5-y OS 78% 10-y OS 64% 5-y and 10-y PFS 80%
Akyurek et al. <sup>30</sup>	n = 35 All myxopapillary	RT 22 GTR 21 STR 13 PE 1	Median 50.4Gy (range 44.3–56Gy) Median fraction 1.8Gy (range 1.5Gy–2Gy)	5-y and 10-y OS 97% 5-y PFS 70% 10-y PFS 62%
Volpp et al. <sup>31</sup>	n = 23 15 ependymoma 6 myxopapillary 2 not given	RT 5 GTR 9 STR 14	Mean 45Gy (range 39–50.4Gy) Fraction 1.8Gy	5-y OS 77% 9-y OS 63%


**Abbreviations:** 10-y OS = 10-y overall survival; 5-y OS = 5-y overall survival; PE = only biopsy taken; PTR = partial tumor resection; TMZ = temozolomide.

control. Several studies compared the outcomes compared to the prescribed dose. Zorlu et al. found in a study of 26 patients an OS trend for patients receiving more than 45Gy or 45Gy or less with 5-year OS of 48% versus 29% (log rank,  $P = .2$ ), respectively.<sup>15</sup> Corradini et al. found a similar but significant relationship for patients receiving dose levels of 45Gy or more versus less than 45Gy with a mean OS of 64.0 months versus 2.5 months for less than 45Gy ( $P < .001$ ) in a cohort of 16 patients.<sup>13</sup> Similar dose relations were found for 40Gy or more versus less than 40Gy<sup>18</sup> and 35Gy,<sup>37</sup> preferring the higher dose in each of those models. The NCCN guidelines of CNS cancers (Version 1.2023) recommend to apply doses ranging from 45 to 54Gy in 1.8Gy dose per fraction for spinal tumors, not specifying the exact entity. Below the conus medullaris doses up to 60Gy (59.4Gy in 1.8Gy fractions) are to be considered according to histology.

Concerning treatment technique, photon therapy with intensity-modulated radiotherapy (IMRT) remains the standard.<sup>17,22</sup> An example of an IMRT plan can be seen in

Figure 2, which represents an ependymoma patient, but does not significantly differ from plans for glioma patients. A comparison of modern photon versus proton therapy in a cohort study by Kahn et al. shows a worse impact on survival concerning protons versus photons (hazard ratio = 40,  $P = .02$ ), despite of the proton cohort having more favorable demographics.<sup>17</sup> The authors, however, note that the limited sample size of patients treated with proton therapy ( $N = 10$ ) is insufficient to draw definitive conclusions regarding the superiority of photons ( $N = 22$ ).<sup>17</sup> But more data concerning a comparison of different RT techniques are warranted.

Upon literature review, it becomes evident that definitive treatment regimens in both HGSG and LGSG remain elusive, highlighting the necessity for prospective trials that incorporate more refined treatment regimens. Notably, some authors have reported encouraging outcomes through the incorporation of temozolomide in cohort studies with a limited sample size.<sup>13,33,38</sup> A summary of the most important treatment decisions is presented in Figure 2.



**Figure 2.** Flowchart with key treatment decisions for radiotherapy of spinal glioma (Oxford Level of evidence 3b).

## Spinal Ependymoma

Adult ependymomas are relatively rare tumors that are most commonly found in the brain but make up about 18% of all spinal cord tumors.<sup>39</sup> The latest WHO classification of CNS tumors, updated in 2021, classifies ependymomas based on their location and molecular characteristics.<sup>32</sup> Spinal ependymomas are recognized as a distinct entity, characterized by molecular definition through MYCN amplification.<sup>32</sup> Depending on their histopathological features, these tumors can be assigned a grade of 2 or 3. Notably, the term “anaplastic” is no longer employed to describe grade 3 ependymomas in the updated classification.<sup>32,40</sup> In the CNS WHO 2021 classification, myxopapillary ependymoma remains an independent entity. However, its grading has been reclassified from grade 1 to grade 2. This change is attributed to its high recurrence rate, which is comparable to other grade 2 spinal ependymomas.<sup>32</sup> Regarding treatment, the primary goal should be achieving optimal GTR, which results in the most favorable outcomes.<sup>27,28,31,41</sup> As the most frequent site of recurrence is typically at the primary site, adjuvant RT is typically administered locally to increase local control.<sup>31,42,43</sup>


As ependymomas represent the third most frequent CNS tumor for children, most treatment recommendations originate from pediatric protocols.<sup>44-47</sup> An early report from 1984 by Read et al. with 79 ependymomas (including 26 spinal cases) with no specified subtype suggested that adjuvant radiotherapy might be beneficial for all ependymoma patients, regardless of their resection status.<sup>48</sup> However, this perspective was subsequently challenged by later investigations. For instance, Lee et al. stated in 1998 that RT should be only considered for cases where GTR could not be achieved.<sup>27,49</sup> Most of the existing literature concurs that radiotherapy is advisable in cases of

residual tumor after surgery, as local control is only about 30%–50% after subtotal resection (STR), and is increased up to 60%–100% after RT.<sup>25,27,29,41,50,51</sup>


While non-myxopapillary spinal ependymoma does not seem to require adjuvant radiotherapy following GTR,<sup>41,50</sup> myxopapillary ependymomas (MPE) are different in this regard. Despite exhibiting a more favorable OS compared to other ependymoma subtypes, MPE present a relatively high recurrence rate (as reported by Boström et al. at 19%) even after GTR.<sup>52,53</sup> Several trials dedicated to the treatment of MPE show that adjuvant treatment might also be required after complete resection. For instance, Akyurek et al. in 2006, Pica et al. in 2009, and Tsai et al. in 2014 conducted analyses involving only patients with myxopapillary ependymoma, concluding that adjuvant radiotherapy should be administered for MPR regardless of the extent of resection.<sup>26,28,30</sup> In contrast to the results of the mentioned study, Lee SH et al. demonstrated different findings in their study involving 61 patients, 24 of whom had MPE. Their analysis did not show a significant difference in 10-year progression-free survival (PFS) between patients who underwent GTR with and without adjuvant radiotherapy ( $P = .771$ ).<sup>27</sup> However, it is important to note that this study did not specifically examine MPE separately. More details of the data presented are listed in Table 1 and presented in Figure 3.

Radiation doses range from 44Gy to 54Gy in dose per fraction of 1.8/2.0Gy in the majority of the literature, matching to the aforementioned recommendations of the NCCN guidelines.<sup>25,26,27,50</sup> The highest reported dose was 59.4Gy in 1.8Gy fraction dose, which was typically employed for ependymomas located in the lumbosacral region.<sup>25</sup> This choice is attributed to the cauda equina being less susceptible to radiation damage compared to the spinal cord itself.<sup>25,26</sup> Pica et al. compared doses of 50.4Gy and higher with lower doses for myxopapillary





**Figure 3.** Flowchart with key treatment decisions for radiotherapy of spinal ependymoma (Oxford Level of evidence 3b).



**Figure 4.** Flowchart with key treatment decisions for radiotherapy of spinal meningioma (Oxford Level of evidence 4).


ependymoma and found a benefit for doses of 50.4Gy or above (5-year PFS 74.8% vs. 50.4%).<sup>28</sup> In line with this data, the EANO guidelines recommend applying postoperative doses of 45–54Gy in conventionally fractionated regimens as 45Gy seems to be the threshold to worse control, and at least 50Gy for MPE after STR.<sup>47</sup> As mentioned in the beginning, critical doses begin above 55Gy (in children even above 40Gy) as the risk for myelopathy increases further than 2%.<sup>2,3</sup> Concerning the size of the irradiation field, the NCCN recommends a craniocaudal expansion of the gross tumor volume by 1–2 cm, the EANO guideline, however, only 5–10 mm.<sup>47</sup> An example of a treatment plan can be seen in [Figure 5](#). But, traditionally, also 2 vertebral bodies above and below the volume were included.

While some studies have explored the use of stereotactic body radiotherapy, this approach has not yet been widely integrated into standard treatment recommendations,

and is only recommended as an alternative for local relapses.<sup>47</sup> Unlike pediatric patients, larger studies focusing on proton therapy for spinal ependymoma are lacking.<sup>54,55</sup> Still, the EANO guidelines mention proton therapy as an option next to conventional 3-dimensional techniques and intensity-modulated arc therapy.<sup>47</sup> Currently, fractionated photon RT with doses typically around 50.4Gy delivered in 1.8Gy dose per fraction remains the primary approach for radiation therapy in cases of spinal ependymoma.

## Spinal Meningioma

Primary spinal meningiomas are rare, and surgical resection generally serves as the primary treatment approach, effectively addressing the majority of issues associated with



**Figure 5.** A treatment plan of a patient with spinal ependymoma CNS WHO grade 2 receiving postoperative radiotherapy after subtotal resection. Image A shows the area of resection (inner contour) and the planning target volume (PTV, outer contour) covering the resection area with an axial margin of 1.2 cm and a craniocaudal margin of 2.0 cm. Image B shows the dose distribution of the respective plan prescribed to 50.4 Gy in 28 fractions. The inner orange isodose represents 95% of the prescription dose, yellow 90%, green 80%, turquoise 70%, and blue 50%.

these tumors.<sup>56</sup> However, there is a paucity of available literature that specifically addresses the use of postoperative RT. The largest cohort analysis of radiotherapy for spinal meningiomas involved the examination of 268 patients who received radiotherapy from a total of 10 458 patients in the database.<sup>57</sup> Among these cases, 137 patients underwent RT alone, while 131 received a combination of RT and surgery.<sup>57</sup> Although this analysis did not demonstrate a significant survival advantage for patients who underwent radiotherapy, it appears that patients with specific risk factors, such as tumor size or grade 2 and 3 meningiomas, were more inclined to receive radiotherapy. This observation suggests a potential bias in patient selection within the study.

Most patients who underwent adjuvant RT for meningiomas were treated with conventionally fractionated regimens delivering doses of 50.4 to 54 Gy in 1.8 Gy fractions.<sup>57–59</sup> Although stereotactic radiotherapy has been suggested as a viable alternative to primary resection, limited data exist in this regard.<sup>60</sup> Due to the scarcity of information regarding RT for spinal meningiomas, it is advisable to adhere to recommendations for cranial meningiomas as outlined in the EANO guidelines.<sup>56</sup> The most important decisions are presented in Figure 4. However, given the lack of real data, studies, preferably prospective, are warranted.

## Conclusions

Despite of limited evidence, RT is the main treatment, next to surgery, for the most frequently observed spinal tumors.<sup>35,47,56</sup> Typically, surgery is the preferred choice, while RT serves as a postoperative treatment in case of subtotal resection or high recurrence rate of the tumor.<sup>22,27,28,37,57</sup> As demonstrated in the previous sections, most evidence is generated in cohort studies with rather small case series. Large registry studies could be helpful to gather more

information about treatment schedules. Furthermore, it is expected that the histology of the tumor will have a more significant impact on the appropriate prescription doses, as seen in the example of the recommendation to deliver a higher dose for MPE.<sup>47</sup> Advanced techniques and novel technologies need to be further explored to optimize treatment outcomes and minimize damage to surrounding tissues. Additionally, more evidence is required to evaluate the risk of myelopathy associated with delivering high doses to large/lengthy volumes of the spinal cord. But so far, conventionally fractionated RT remains the first choice when treating spinal tumors. To define the optimal indications and prescription schemes for RT of spinal tumors further data, especially prospective data, are warranted.

## Funding

None declared.

## Conflict of interest statement

M.N. received speaker honoraria from Brainlab that did not affect the current work. R.B., E.H., and C.B. state that they have no conflicts of interest.

## References

1. Carlos-Escalante JA, Paz-López A, Cacho-Díaz B, et al. Primary benign tumors of the spinal canal. *World Neurosurg.* 2022;164:178–198.

2. Schultheiss TE, Stephens LC, Peters LJ. Survival in radiation myelopathy. *Int J Radiat Oncol Biol Phys*. 1986;12(10):1765–1769.
3. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. *Int J Radiat Oncol Biol Phys*. 2010;76(3 Suppl):S42–S49.
4. Marcus RB, Jr, Million RR. The incidence of myelitis after irradiation of the cervical spinal cord. *Int J Radiat Oncol Biol Phys*. 1990;19(1):3–8.
5. Wong CS, Fehlings MG, Sahgal A. Pathobiology of radiation myelopathy and strategies to mitigate injury. *Spinal Cord*. 2015;53(8):574–580.
6. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. *Int J Radiat Oncol Biol Phys*. 2011;79(5):1487–1495.
7. Bodensohn R, Hadi I, Fleischmann DF, et al. Bevacizumab as a treatment option for radiation necrosis after cranial radiation therapy: a retrospective monocentric analysis. *Strahlenther Onkol*. 2020;196(1):70–76.
8. Shah N, Ranjan S. Successful treatment of quadriplegia from radiation myelopathy with bevacizumab in a patient with metastatic breast cancer. *BMJ Case Rep*. 2022;15(2).
9. Cañedo G, Solís I, González-San Segundo C, Madero L, Lassaletta A. Treatment of radiation-induced myelopathy with bevacizumab. *Clin Transl Oncol*. 2020;22(6):957–960.
10. Psimaras D, Tafani C, Ducray F, et al. Bevacizumab in late-onset radiation-induced myelopathy. *Neurology*. 2016;86(5):454–457.
11. Chamberlain MC, Eaton KD, Fink J. Radiation-induced myelopathy: treatment with bevacizumab. *Arch Neurol*. 2011;68(12):1608–1609.
12. Naghavi S, Motahharynia A, Fatemi F, et al. The benefit of intravenous immune globulin in the treatment of delayed radiation myelopathy. *Strahlenther Onkol*. 2023.
13. Corradini S, Hadi I, Hankel V, et al. Radiotherapy of spinal cord gliomas: a retrospective mono-institutional analysis. *Strahlenther Onkol*. 2016;192(3):139–145.
14. Rodrigues GB, Waldron JN, Wong CS, Laperriere NJ. A retrospective analysis of 52 cases of spinal cord glioma managed with radiation therapy. *International journal of radiation oncology, biology, physics*. 2000;48(3):837–842. doi:10.1016/S0360-3016(00)00690-8
15. Zorlu F, Ozyigit G, Gurkaynak M, et al. Postoperative radiotherapy results in primary spinal cord astrocytomas. *Radiother Oncol*. 2005;74(1):45–48.
16. Shirato H, Kamada T, Hida K, et al. The role of radiotherapy in the management of spinal cord glioma. *International journal of radiation oncology, biology, physics*. 1995;33(2):323–328. doi:10.1016/0360-3016(95)00179-3
17. Kahn J, Loeffler JS, Niemierko A, et al. Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques. *Int J Radiat Oncol Biol Phys*. 2011;81(1):232–238.
18. Garcia DM. Primary spinal cord tumors treated with surgery and postoperative irradiation. *Int J Radiat Oncol Biol Phys*. 1985;11(11):1933–1939.
19. Linstadt DE, Wara WM, Leibel SA, Gutin PH, Wilson CB, Sheline GE. Postoperative radiotherapy of primary spinal cord tumors. *International journal of radiation oncology, biology, physics*. Jun 1989;16(6):1397–1403. doi:10.1016/0360-3016(89)90940-1
20. Sandler HM, Papadopoulos SM, Thornton AF, Jr., Ross DA. Spinal cord astrocytomas: results of therapy. *Neurosurgery*. 1992;30(4):490–493. doi:10.1227/00006123-199204000-00003
21. Minehan KJ, Brown PD, Scheithauer BW, Krauss WE, Wright MP. Prognosis and treatment of spinal cord astrocytoma. *Int J Radiat Oncol Biol Phys*. 2009;73(3):727–733.
22. Nunna RS, Khalid S, Ryoo JS, Mehta AI. Adult primary high-grade spinal glioma: a nationwide analysis of current trends in treatment and outcomes. *J Neurooncol*. 2020;147(3):633–641.
23. Shaw EG, Evans RG, Scheithauer BW, Ilstrup DM, Earle JD. Radiotherapeutic management of adult intraspinal ependymomas. *International journal of radiation oncology, biology, physics*. 1986;12(3):323–327. doi:10.1016/0360-3016(86)90345-7
24. Choi SH, Yoon HI, Yi S, et al. Treatment outcomes of radiotherapy for primary spinal cord glioma. *Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft [et al]*. 2019;195(2):164–174. Behandlungsergebnisse der Strahlentherapie beim primären Rückenmarksgliom. doi:10.1007/s00066-018-1366-3
25. Byun HK, Yi S, Yoon HI, et al. Clinical outcomes of radiotherapy for spinal cord ependymoma with adverse prognostic features: a single-center study. *J Neurooncol*. 2018;140(3):649–657.
26. Tsai CJ, Wang Y, Allen PK, et al. Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson Cancer Center experience. *Neurosurgery*. 2014;75(3):205–214; discussion 213–4.
27. Lee SH, Chung CK, Kim CH, et al. Long-term outcomes of surgical resection with or without adjuvant radiation therapy for treatment of spinal ependymoma: a retrospective multicenter study by the Korea Spinal Oncology Research Group. *Neuro Oncol*. 2013;15(7):921–929.
28. Pica A, Miller R, Villà S, et al. The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. *Int J Radiat Oncol Biol Phys*. 2009;74(4):1114–1120.
29. Wahab SH, Simpson JR, Michalski JM, Mansur DB. Long term outcome with post-operative radiation therapy for spinal canal ependymoma. *J Neurooncol*. 2007;83(1):85–89.
30. Akyurek S, Chang EL, Yu TK, et al. Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at MD Anderson Cancer Center. *J Neurooncol*. 2006;80(2):177–183.
31. Volpp PB, Han K, Kagan AR, Tome M. Outcomes in treatment for intradural spinal cord ependymomas. *Int J Radiat Oncol Biol Phys*. 2007;69(4):1199–1204.
32. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol*. 2021;23(8):1231–1251.
33. Kim WH, Yoon SH, Kim CY, et al. Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review. *J Neurooncol*. 2011;101(2):247–254.
34. McGirt MJ, Goldstein IM, Chaichana KL, et al. Extent of surgical resection of malignant astrocytomas of the spinal cord: outcome analysis of 35 patients. *Neurosurgery*. 2008;63(1):55–60; discussion 60–1.
35. Anghileri E, Broggi M, Mazzapicchi E, et al. Therapeutic approaches in adult primary spinal cord astrocytoma: a systematic review. *Cancers (Basel)*. 2022;14(5):1292.
36. Hamilton KR, Lee SS, Urquhart JC, Jonker BP. A systematic review of outcome in intramedullary ependymoma and astrocytoma. *J Clin Neurosci*. 2019;63:168–175.
37. Minehan KJ, Shaw EG, Scheithauer BW, Davis DL, Onofrio BM. Spinal cord astrocytoma: pathological and treatment considerations. *J Neurosurg*. 1995;83(4):590–595.
38. Hernández-Durán S, Bregy A, Shah AH, et al. Primary spinal cord glioblastoma multiforme treated with temozolomide. *J Clin Neurosci*. 2015;22(12):1877–1882.
39. Peschel RE, Kapp DS, Cardinale F, Manuelidis EE. Ependymomas of the spinal cord. *Int J Radiat Oncol Biol Phys*. 1983;9(7):1093–1096.
40. Ellison DW, Aldape KD, Capper D, et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. *Brain Pathol*. 2020;30(5):863–866.
41. Lee TT, Gromelski EB, Green BA. Surgical treatment of spinal ependymoma and post-operative radiotherapy. *Acta Neurochir*. 1998;140(4):309–313.
42. Garrett PG, Simpson WJ. Ependymomas: results of radiation treatment. *Int J Radiat Oncol Biol Phys*. 1983;9(8):1121–1124.



43. Kopelson G, Linggood RM, Kleinman GM, Doucette J, Wang CC. Management of intramedullary spinal cord tumors. *Radiology*. 1980;135(2):473–479.
44. Elsamadicy AA, Koo AB, David WB, et al. Comparison of epidemiology, treatments, and outcomes in pediatric versus adult ependymoma. *Neuro-Oncol Adv*. 2020;2(1):vdaa019.
45. McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. *J Neurosurg*. 2009;110(4):725–729.
46. Mavroidis P, Ferreira BC, Shi C, et al. Comparison of the helical tomotherapy and MLC-based IMRT radiation modalities in treating brain and cranio-spinal tumors. *Technol Cancer Res Treat*. 2009;8(1):3–14.
47. Rudà R, Reifenberger G, Frappaz D, et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. *Neuro Oncol*. 2018;20(4):445–456.
48. Read G. The treatment of ependymoma of the brain or spinal canal by radiotherapy: a report of 79 cases. *Clin Radiol*. 1984;35(2):163–166.
49. Wen BC, Hussey DH, Hitchon PW, et al. The role of radiation therapy in the management of ependymomas of the spinal cord. *Int J Radiat Oncol Biol Phys*. 1991;20(4):781–786.
50. Whitaker SJ, Bessell EM, Ashley SE, et al. Postoperative radiotherapy in the management of spinal cord ependymoma. *J Neurosurg*. 1991;74(5):720–728.
51. Oh MC, Ivan ME, Sun MZ, et al. Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas. *Neuro Oncol*. 2013;15(2):208–215.
52. Pędzwiatr K, Skowrońska-Gardas A, Chojnacka M. Spinal cord ependymoma in children—results of postoperative radiotherapy. *Radiother Oncol*. 2013;106(2):181–185.
53. Boström A, von Lehe M, Hartmann W, et al. Surgery for spinal cord ependymomas: outcome and prognostic factors. *Neurosurgery*. 2011;68(2):302–308; discussion 309.
54. Indelicato DJ, Ioakeim-Ioannidou M, Grippin AJ, et al. Bicentric treatment outcomes after proton therapy for nonmyxopapillary high-grade spinal cord ependymoma in children. *Int J Radiat Oncol Biol Phys*. 2022;112(2):335–341.
55. Amsbaugh MJ, Grosshans DR, McAleer MF, et al. Proton therapy for spinal ependymomas: planning, acute toxicities, and preliminary outcomes. *Int J Radiat Oncol Biol Phys*. 2012;83(5):1419–1424.
56. Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. *Neuro Oncol*. 2021;23(11):1821–1834.
57. Yolcu YU, Goyal A, Alvi MA, Moinuddin FM, Bydon M. Trends in the utilization of radiotherapy for spinal meningiomas: insights from the 2004–2015 National Cancer Database. *Neurosurg Focus*. 2019;46(6):E6.
58. Gezen F, Kahraman S, Canakci Z, Bedük A. Review of 36 cases of spinal cord meningioma. *Spine (Phila Pa 1976)*. 2000;25(6):727–731.
59. Noh SH, Kim KH, Shin DA, et al. Treatment outcomes of 17 patients with atypical spinal meningioma, including 4 with metastases: a retrospective observational study. *Spine J*. 2019;19(2):276–284.
60. Meola A, Soltys S, Schmitt A, Gerszten PC, Chang SD. Stereotactic radiosurgery for benign spinal tumors. *Neurosurg Clin N Am*. 2020;31(2):231–235.